Background Owing to its low risk of adverse effects, teicoplanin has been extensively used
in patients with infections caused by MRSA. To promote the better management of patients …

Therapeutic drug monitoring (TDM) of teicoplanin is aimed at minimizing the clinical impact
of pharmacokinetic variability; however, its benefits are still being defined. We performed a …

Background Teicoplanin is a glycopeptide antibiotic that is widely used in clinical practice for
the treatment of infections caused by drug-resistant Gram-positive bacteria. The aim of this …

Objectives: Teicoplanin, an antibiotic, has poor clinical efficacy when using the current drug
label's recommended regimen, which is approved by the China Food and Drug …

An initial loading procedure has been recommended to enable teicoplanin to promptly reach
an effective serum concentration for the treatment of methicillin-resistant Staphylococcus …

In the treatment of severe MRSA infections such as endocarditis, more than 20 mg/L of
plasma trough concentration (C min) is recommended for teicoplanin; however, in the …

Background Teicoplanin is a glycopeptide antibiotic that has been used to treat serious,
invasive infections caused by Gram-positive bacteria. The area under the drug concentration …

Objectives An analysis of the trough serum concentrations sent to the UK Antimicrobial
Reference Laboratory for teicoplanin therapeutic drug monitoring (TDM). Methods All trough …

Minimum inhibitory concentration (MIC) creep in vancomycin has prompted guidelines that
recommend a target trough concentration (C min) of 15–20 mg/L, and it is also considered …

We evaluated the clinical efficacy and safety of teicoplanin according to the
pharmacokinetics (PK) therapeutic level achieved in patients with renal dysfunction. Target …